The Genzyme deal: what's the hold-up?
This article was originally published in Scrip
Executive Summary
With expectations running high that the final terms of the acquisition of Genzyme by Sanofi-Aventis would be announced with Sanofi’s quarterly results on Wednesday, the absence of not just the announcement, but any colour on the negotiations may be worrying to some investors.